Pincus Capital Management LP Makes New Investment in Eli Lilly and Company $LLY

Pincus Capital Management LP acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 2,555 shares of the company’s stock, valued at approximately $2,746,000. Eli Lilly and Company accounts for about 1.8% of Pincus Capital Management LP’s holdings, making the stock its 13th biggest position.

Several other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares during the period. State Street Corp lifted its position in shares of Eli Lilly and Company by 0.6% during the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock worth $26,496,364,000 after purchasing an additional 219,590 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock worth $11,112,164,000 after purchasing an additional 574,229 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $12,976,634,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 2.3%

LLY stock opened at $1,079.96 on Tuesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,149.10. The firm has a fifty day moving average price of $959.18 and a two-hundred day moving average price of $1,010.74. The firm has a market cap of $1.02 trillion, a price-to-earnings ratio of 38.36, a PEG ratio of 1.21 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the previous year, the firm earned $3.34 earnings per share. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark now covers Eli Lilly’s full obesity drug portfolio, including the newly approved oral therapy Foundayo and injectable Zepbound. With all three major U.S. PBMs covering Lilly’s obesity medicines, the company gets broader insurance access and a stronger commercial outlook for its weight-loss franchise. PBM Coverage Of Eli Lilly Obesity Drugs Reshapes Growth And Pricing Outlook
• Positive Sentiment: Lilly announced a major Phase 3 win for Retevmo (selpercatinib), which cut the risk of recurrence or death by 83% in early-stage RET fusion-positive lung cancer. The data could expand the drug’s use and add to Lilly’s oncology growth pipeline. Unit of China’s Haisco, Eli Lilly sign collaboration, licensing deals
• Positive Sentiment: The company also announced new licensing and collaboration deals in Asia, including agreements with Hanmi and Haisco. Investors may view the deal-making as evidence that Lilly is actively building its next wave of products beyond obesity drugs. Lilly Continues Its Acquisition Spree, Inks Two Asia Partnerships Today
• Neutral Sentiment: Several commentary pieces highlighted Lilly as one of the market’s top momentum stocks, and noted bullish analyst sentiment and strong Q1 revenue growth. These reports reinforce positive expectations, but they do not add materially new fundamentals. These 8 Words From Eli Lilly’s CEO Have Wall Street Turning Bullish
• Neutral Sentiment: One industry update noted Novo Nordisk’s oral GLP-1 pill is still outselling Lilly’s competing tablet, though growth is slowing. That suggests the obesity market remains highly competitive even as Lilly expands access. Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows
• Negative Sentiment: There was also a widely circulated note that Lilly shares had been trading down earlier in the period, but the article did not point to a new company-specific problem. Insider selling data in one report may also weigh on sentiment, though it is not necessarily a near-term fundamental issue. Eli Lilly and Company (NYSE:LLY) Trading Down 1.9% – What’s Next?

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research report on Thursday, February 19th. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Finally, UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.